Is Viatris Inc (VTRS) undervalued? · rev $14.74B
Viatris Inc (VTRS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Viatris Inc (VTRS) looks cheap on cached numbers — not a DCF toy and not a buy alert.
Latest reported VTRS revenue for 2024-12-31 was $14.74B. Net income was -$634.2M. Revenue was down 4.5% from 2023-12-31 to 2024-12-31. VTRS currently screens at market cap $10.83B.
VTRS currently screens at market cap $10.83B. Cheap versus history or peers still needs a filing reason; a low multiple can be a value trap.
A new VTRS 10-Q can flip this screen overnight. The SEC page is the source.
Not investment advice. Compare VTRS to the stock page model before you treat a low multiple as a gift.
Not investment advice.